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Background: High serum concentrations of small dense low-density lipoprotein cholesterol (sd-
LDL-c) particles are associated with risk of cardiovascular disease (CVD). Their clinical application 
has been hindered as a consequence of the laborious current method used for their quantification.
Objective: Optimize a simple and fast precipitation method to isolate sd-LDL particles and 
establish a reference interval in a Mediterranean population.
Materials and methods: Forty-five serum samples were collected, and sd-LDL particles 
were isolated using a modified heparin-Mg2+ precipitation method. sd-LDL-c concentration 
was calculated by subtracting high-density lipoprotein cholesterol (HDL-c) from the total 
cholesterol measured in the supernatant. This method was compared with the reference method 
(ultracentrifugation). Reference values were estimated according to the Clinical and Labora-
tory Standards Institute and The International Federation of Clinical Chemistry and Laboratory 
Medicine recommendations. sd-LDL-c concentration was measured in serums from 79 subjects 
with no lipid metabolism abnormalities.
Results: The Passing–Bablok regression equation is y = 1.52 (0.72 to 1.73) + 0.07x (−0.1 to 
0.13), demonstrating no significant statistical differences between the modified precipitation 
method and the ultracentrifugation reference method. Similarly, no differences were detected 
when considering only sd-LDL-c from dyslipidemic patients, since the modifications added 
to the precipitation method facilitated the proper sedimentation of triglycerides and other 
lipoproteins. The reference interval for sd-LDL-c concentration estimated in a Mediterranean 
population was 0.04–0.47 mmol/L.
Conclusion: An optimization of the heparin-Mg2+ precipitation method for sd-LDL particle 
isolation was performed, and reference intervals were established in a Spanish Mediterranean 
population. Measured values were equivalent to those obtained with the reference method, 
assuring its clinical application when tested in both normolipidemic and dyslipidemic subjects.
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Introduction
High concentration of low-density lipoprotein cholesterol (LDL-c) is one of the major 
coronary heart disease (CHD) risk factors.1 The LDLs are a heterogeneous group of 
particles differing in size and density.2 Small dense LDL (sd-LDL) particles are more 
atherogenic than large buoyant LDL particles (lb-LDL)3–5 and are associated with CHD 
risk.6–9 These particles are formed as a consequence of a high activity of cholesteryl 
ester transfer protein and hepatic lipase enzyme in subjects with elevated triglyceride 
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(TG) concentration.10,11 The increased atherogenicity of sd-
LDL particles is due to their small size and density, which 
facilitates their infiltration in the subendothelial layer of 
arteries. It is also known that sd-LDL particles have a dif-
ferent apolipoprotein B conformation with a lower affinity 
for LDL receptors in the liver resulting in a decrease of LDL 
particle clearance.12 The sd-LDL particles are associated with 
hypertriglyceridemia and low HDL-c concentration. These 
three lipid abnormalities are usually called the lipid triad 
(LT) and are frequent in patients with premature CHD.13–16 
The LT is a common finding in atherogenic dyslipidemia 
(AD) associated with insulin resistance, abdominal obesity 
and metabolic syndrome. Although LDL-c-lowering drugs 
are effective in AD management, in some subjects, the car-
diovascular disease (CVD) risk is not increased although 
not achieving LDL-c targets.17–19 On the contrary, >20% of 
patients who had achieved LDL-c ≤1.81 mmol/L still show 
an atherogenic plaque progression.19,20 Therefore, studying 
the contribution of individual components of the LT to the 
atherogenic process can lead to an important improvement in 
the current understanding of the residual CVD risk in subjects 
who are on target of LDL-c concentrations.
TGs and HDL-c are usually included in the lipid profile, 
but the determination of sd-LDL particles is not performed 
in the routine analysis as its quantification is traditionally 
measured by ultracentrifugation that requires expensive 
equipment, complicated techniques and long assay times.21 
Recently, new methods have been developed22 such as the 
nuclear magnetic resonance (NMR)23,24 that determines the 
size and number of LDL particles simultaneously and the 
Quantimetrix Lipoprint LDL System that quantifies LDL 
particle size subfractions25 or an automatized homogeneous 
assay for sd-LDL-c quantification,26–28 but both of them have 
limited clinical use because of their cost.
A precipitation method for sd-LDL particle isolation 
with heparin-Mg2+ was developed in 2003,29 being an easy 
and inexpensive method. However, this method has not been 
adapted to routine laboratories, and the reference values and 
the clinical utility in healthy and dyslipidemic population 
have not been studied. Therefore, it is interesting to optimize 
this method, check its interchangeability with ultracentrifuga-
tion, which is considered the reference method, and establish 
reference values in order to improve its contribution to clini-
cal assessment.
CVD still remains a major cause of disability and 
premature death through the world, despite a number of 
breakthroughs in its prevention diagnosis and treatment. 
The accuracy in the diagnosis will decrease cardiovascular 
events as patients will benefit from more effective treatment.30 
Although CVD mortality rates are lower in the southern 
countries of Europe, frequently considered to be a conse-
quence of the Mediterranean diet, in Spain the hazard ratio 
estimated for CVD is 0.89% (95% confidence interval [CI]: 
0.71–1.12)31 and for AD is 5.7%.19 Nevertheless, reference 
values for sd-LDL-c concentrations have not yet been studied 
in a Mediterranean population by this method. Therefore, the 
classification of patients according to their cardiovascular risk 
based on sd-LDL-c has not been possible. Effective detection 
of pathological sd-LDL-c concentrations in subjects with 
AD who have achieved LDL-c target could be very useful 
since it may explain the CVD residual risk associated to the 
LT.14,32–35 Subjects with a higher CVD risk with sd-LDL-c 
concentration above the reference value but normal LDL-c 
concentration would benefit from a combined therapy with 
statins plus fenofibrates instead of statin monotherapy or 
other therapeutic strategies.13,36–38
The evidence that correlates sd-LDL particles and 
CVD14,33,34,35,36 is clear. However, the current lack of practi-
cability for its quantification in the routine laboratory and 
the absence of reference values in Mediterranean population 
make difficult to implement its measure in clinical laborato-
ries. Achieving an inexpensive, easy and short time analysis 
method could facilitate sd-LDL-c concentration measure-
ment in the clinical practice as a new dyslipidemia biomarker.
The aims of this study are to optimize a modification of 
the heparin-Mg2+ precipitation method for sd-LDL particle 
isolation and subsequent quantification, assess the results 
interchangeability with the reference method, and establish 





To evaluate the interchangeability with the reference 
method – ultracentrifugation – patients of both sexes with and 
without dyslipidemia attending to the clinical laboratory for 
their routine checkup were recruited. First, 30 serums from 
patients (aged 50–70 years) with no abnormal lipid concen-
trations according to the National Cholesterol Education 
Program (NCEP) guidelines were collected. In addition, 15 
serums from patients (aged 55–75 years) with mixed dys-
lipidemia diagnosed in the Risk Cardiovascular Functional 
Unit of our hospital were selected.
In order to guarantee the method applicability in 
hypertriglyceridemic samples, serums from 50 severe 
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dyslipidemic patients belonging to PREDIMED-PLUS 
trial39 were analyzed, and the correct isolation of sd-LDL 
was also checked. The inclusion criteria for these patients 
were the same as in PREDIMED-PLUS: adult males aged 
55–75 years and adult females aged 60–75 years with a 
body mass index (BMI) ≥27 and <40 kg/m2 and who meet 
at least three criteria for the metabolic syndrome considered 
for the NCEP.
Measurement of sd-LDL-c concentration
All serum samples were collected in tubes without anti-
coagulant and with separating gel (Vacuette ref: 456069). 
Serum samples were conserved at 80°C until analysis. The 
precipitation assay was performed during next 2 weeks after 
blood extraction. The sd-LDL particles were isolated with 
a precipitation reagent that contains 150 U/mL heparin-
Na+ (H3393; Sigma-Aldrich) and 90 mmol/L MgCl
2
. Each 
sample was prepared by mixing 300 µL of serum with 300 µL 
of the precipitation reagent and incubated for 10 min at 37°C. 
Then, the samples were maintained for 15 min at 0°C and 
centrifugated at 21913× g (14000 rpm) for 15 min at 4°C 
(centrifuge 6K15; Sigma-Aldrich). After that, the lipopro-
teins with a density <1.044 g/mL remained at the bottom 
of the tube forming a yellow precipitate. The supernatant is 
clear and contains HDL and sd-LDL particles with a density 
between 1.044 and 1.063 g/mL. An aliquot of the superna-
tant was removed for HDL-c and cholesterol analyses at the 
Cobas 711 (Roche® Diagnostics). The reagents used in the 
homogeneous automatized assays were Colesterol Liq Gen 
2 for cholesterol and HDL-Cholesterol plus 3rd generation 
HDL-c. As the supernatant only contains cholesterol from 
HDL and sd-LDL lipoproteins, the sd-LDL-c concentra-
tion was estimated by subtracting HDL-c from the total 
cholesterol.
Precipitation method modifications
We adapted the precipitation method to the available equip-
ment in our laboratory and reproduced the Hirano experiment 
cooling to 4°C and centrifuging at 14000 rpm. To promote the 
precipitate formation instead of centrifuging at 15000 rpm, 
we placed the samples at 0°C for 15 min. As a consequence 
of the lower temperature, the precipitate is packed tightly 
and larger numbers of samples can be processed before the 
precipitate begins to dissolve avoiding rich TG lipoproteins 
interferences. These modifications successfully ensure the 
sd-LDL particles isolation preserving the supernatant for 
longer until the separation from the sedimented lipoproteins 
takes place.
Method comparison
To validate the measuring procedure modifications, we 
compared sd-LDL particles after the precipitation and those 
obtained by the ultracentrifugation. To confirm the inter-
changeability between results obtained by both methods, 
sd-LDL-c concentration was measured in 30 normolipidemic 
and 15 dyslipidemic samples from patients described in the 
“Subjects” section. The sd-LDL particles were isolated by the 
precipitation assay as described earlier and by ultracentrifuga-
tion (290000× g for 7 h at 16°C). Supernatant obtained by 
both methods was removed, and cholesterol was measured 
at the Cobas 711 (Roche® Diagnostics).
To verify the method applicability in real patients with 
lipid metabolism disorders, we reproduced the precipitation 
conditions in serum collected from 50 patients included in 
the PREDIMED-PLUS trial.
Data were analyzed using Analyse-It v1.72 (Analyse-It 
Software Ltd., Leeds, UK). The outliers were eliminated 
using the Bland–Altman analysis that evaluates bias and 95% 
CI limits of agreement. Differences between methods were 




Seventy-nine participants (33 males), from the North East of 
Spain, aged 18–60 years were recruited. The demographic 
data collected included sex, age, height, weight, BMI, 
lifestyle habits (special diet, alcohol intakes, smokers and 
regular physical activity), family history, medication and gly-
cated hemoglobin, lipids and lipoprotein measurement. We 
excluded subjects with the following conditions: <18 years 
of age, diabetes mellitus, dyslipidemia, pregnancy, cancer 
or undergoing chemotherapy, thyroid disorders, history of 
CVDs, BMI >25 kg/m2, those currently on lipid-lowering 
therapy and lipid concentrations above the cutoff values 
proposed by the NCEP to evaluate the CVD risk. Written 
informed consent was obtained from each subject, and the 
study was approved by the Clinical Research Ethics Commit-
tee of Bellvitge University Hospital. Lipid profile, glycated 
hemoglobin, anthropomorphic characteristics and lifestyle 
habits are specified in Table 1.
Measurement of sd-LDL-c concentration
Blood samples were collected in tubes without anticoagulant 
and with separating gel (Vacuette ref: 456069). Serum aliquots 
from the primary tube were stored at −80°C for a maximum 
of 15 days. All analyses were performed the following 15 days 





after the blood extraction. The sd-LDL particles are isolated 
as described earlier, and then cholesterol and HDL-c were 
measured at the Cobas 711 (Roche® Diagnostics). Finally, 
sd-LDL-c concentration was estimated by subtracting HDL-c 
from the cholesterol measured in the supernatant.
Statistical analysis for the reference interval 
establishment
We performed the reference interval study according to the 
CLSI and The International Federation of Clinical Chemistry 
and Laboratory Medicine recommendations.40 Data were 
analyzed using Analyse-It v1.72 (Analyse-It Software Ltd.). 
Outliers were identified and omitted using a box plot. Data lying 
outside 3 interquartile ranges (IQRs) from the upper or lower 
edge of the box were eliminated. Reference interval partition-
ing test by sex and age was performed using Harris and Boyd’s 
approach. The Anderson–Darling nonparametric test was used 
to study the distribution data. As sd-LDL-c concentrations are 
distributed according to a Gaussian curve, a parametric method 
was used to establish the reference interval. The remainder 95% 
of values was considered to establish the reference interval.
Results
Evaluation of the precipitation method 
modifications
The modifications implemented promote the lipoproteins 
sedimentation when centrifugation at 14000 rpm is carried 
out. In order to facilitate the precipitation, the samples are 
cooled at 0°C. After the centrifugation, the pellet is formed 
and a clear supernatant can be easily removed in the case of 
normolipidemic serum. When assay is performed with lip-
idemic serum, TG aggregates remain on the top of the tube 
hampering the supernatant pipetting. However, the absence 
of TG aggregates sedimentation does not interfere with the 
sd-LDL-c quantification in the supernatant, as long as the 
TG aggregates are carefully removed from the supernatant 
before pipetting it. HDL-c values obtained in the serum 
before the sd-LDL particles isolation are used as a control 
of the precipitation method efficiency. If all the lipoproteins 
with a density >1.044 g/mL should remain in the supernatant 
after the rich TG lipoproteins sedimentation, the HDL-c 
measured in the supernatant should not have any change from 
the HDL-c initial values measured before the precipitation. 
This is a fast and inexpensive method that allows to measure 
sd-LDL-c concentration. Thirty samples can be processed at 
the same time, and 40 min are needed to isolate and quantify 
sd-LDL-c concentration.
Comparison between the precipitation 
method and the ultracentrifugation
The good association between the sd-LDL-c concentration 
measured after sd-LDL particles isolation by the precipita-
tion method and the ultracentrifugation method for both 
normolipidemic and dyslipidemic samples (n=45) is shown 
in the linear equation (R
2
=0.993) provided by the Passing - 
Bablok regression analysis (y=1.52 [0.72 to 1.73] + 0.07 
[−0.1 to 0.13]). Outliers were detected and excluded by the 
Bland–Altman analysis. Passing–Bablok regression analysis 
showed no significant deviation from linearity. The results 
with 95% CI for the slope (1.52 [0.72 to 1.73]) and the 
intercept (0.07 [−0.1 to 0.13]) demonstrate that no constant 
or proportional error was detected.
Reference interval estimation
Comparison of sd-LDL-c concentration in males and females 
demonstrated no distinct partitioning patterns, but sd-LDL-c 
concentrations are higher in males than females (Table 2). Age 
differences were not detected by Harris and Boyd’s test, and 
sd-LDL-c concentrations are not increased with age (Table 3).
Any outliers were detected, and the sd-LDL-c data 
observed a normal distribution (p=0.06). The reference 
interval estimated is 0.04–0.47 mmol/L.
Table 1 Subjects’ characteristics for the reference values 
assessment
Variables Mean (range)
Age, years 31.73 (18–60)
Weight, kg 61.4 (45–82)
BMI, kg/cm2 21.26 (16.9–24.5)
HbA1c (NGSP), % 5.23 (4.38–5.9)
Cholesterol, mmol/L 4.1 (2.1–5.1)
Triglycerides, mmol/L 0.7 (0.35–1.53)
HDL-c concentration, mmol/L 1.67 (1.13–2.63)
LDL-c concentration, mmol/L* 2.16 (0.68–3.12)
Apolipoprotein A, nmol/L 1.39 (0.36–3.30)
Apolipoprotein B, nmol/L 0.78 (0.35–1.99)
sd-LDL-c concentration, mmol/L 0.26 (0.07–0.53)
Smoking, yes, % 13.92
Alcohol, occasionally, % 37.97
Physical activity, occasionally, % 48.10
Note: *Calculated by Friedewald formula.
Abbreviations: BMI, body mass index; HbA1c (NGSP), glycated hemoglobin 
(National Glycohemoglobin Standardization Program units); HDL-c, high-density 
lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; sd-LDL-c, small 
dense low-density lipoprotein cholesterol.
Table 2 sd-LDL-c concentration by sex
Sex Male (n=33) Female (n=49)
sd-LDL-c (mmol/L) 0.26 (0.08–0.53) 0.19 (0.07–0.50)
Note: Data are presented as mean (range).
Abbreviation: sd-LDL-c, small dense low-density lipoprotein cholesterol.




sd-LDL reference values in a Mediterranean population
Discussion
In this study, the original method reported by Hirano has been 
adapted to our laboratory technical conditions. In order to 
overcome such technical limitations, several modifications 
had to be integrated in the precipitation procedure like the 
cooling sample temperature during the rich TG lipoproteins 
sedimentation. Although a small number of samples were 
included in the method comparison, which may be con-
sidered a limitation of this study, slight modifications have 
been made from the original method. The results obtained 
by the original method had already been demonstrated to 
be interchangeable with the reference method in previous 
studies, and our results are consistent with them. Its clini-
cal application has been tested in serum from dyslipidemic 
patients showing no differences in the precipitation procedure 
from the normolipidemic serum. Only serums from patients 
with hypertriglyceridemia showed aggregates that remained 
on the top of the tube. Despite the absence of lipoprotein 
sedimentation, the TG aggregates can be removed from the 
supernatant and no interference in the sd-LDL-c quantifica-
tion was detected.28,29,41
The other aim of this study is to present reference values 
for serum sd-LDL-c concentration in a Mediterranean pop-
ulation from the North East of Spain. The reference value 
for serum sd-LDL-c concentration was 0.04–0.47 mmol/L. 
Thus far, no reference values for sd-LDL-c concentration 
have been reported using this methodology and this is 
not only the case in a Mediterranean population, but in 
other regions  sd-LDL-c concentration also has not been 
estimated in a reference population. The method-specific 
reference values assessment rather than the universal 
reference values improves the decision-making process 
in a clinical setting enabling the CVD risk stratification. 
Regarding the strengths of this study, we determined the 
reference values in subjects who strictly met all the inclu-
sion criteria and who had already completed an application 
form about their lifestyle instead of exporting data from the 
laboratory database, in order to provide the best reference 
intervals for use in preventive medicine.
These reference values were validated in a dyslipidemic 
population from the PREDIMED-PLUS trial.39 Even though 
all the participants are in lipid-lowering therapy, not every 
patient responds to the current treatment in the same way. 
Those who had achieved TG and LDL-c concentration targets 
presented sd-LDL-c concentration within the reference inter-
val estimated. Subjects who still have elevated concentrations 
of TG and LDL-c after the lipid-lowering therapy presented 
sd-LDL-c concentrations higher than the established refer-
ence values. Further information about specific lipid-lowering 
treatments from patients with lower sd-LDL-c concentration 
should be analyzed in future investigations.
Conclusion
This study optimizes the interchangeability of the modified 
heparin-Mg2+ precipitation method and the ultracentrifuga-
tion method. Reference values for sd-LDL-c concentration 
were estimated in a Mediterranean population and proven 
in patients from the PREDIMED-PLUS trial. To our knowl-
edge, it is the first study in which reference values have been 
established using this useful and easy-to-carry-out method. 
Further studies should determine the role of the concentra-
tion of sd-LDL particles in the atheroma progression and the 
severity of CHD, especially in patients with normal LDL-c 
concentrations with diabetes or hypertriglyceridemia and 
other conditions related with AD. Likewise, it would be 
necessary to establish a cutoff value from which the risk of 
CVD is increased compared to healthy individuals. Therefore, 
the measurement of sd-LDL-c concentration by this method 
could be useful to improve the evaluation of cardiovascular 
risk and to tailor preventive strategies in patients with high 
sd-LDL-c. The reference range obtained was from 0.04 to 
0.47 mmol/L.
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